Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Emergent BioSolutions Inc. Director's Dealing 2018

Mar 1, 2018

32870_dirs_2018-03-01_965c425c-1740-4ce6-851a-b13002bab134.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2018-02-27

Reporting Person: Kramer Robert (EVP, Administration and CFO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-02-27 Common Stock A 5917 $0.00 Acquired 88012 Direct
2018-02-27 Common Stock A 5917 $0.00 Acquired 93929 Direct
2018-02-27 Common Stock F 778 $49.64 Disposed 93151 Direct
2018-02-28 Common Stock F 1545 $49.97 Disposed 91606 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-02-27 Employee Stock Option (right to buy) $49.64 A 23670 Acquired 2025-02-26 Common Stock (23670) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 1000 Indirect

Footnotes

F1: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.

F2: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

F3: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2020 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period.

F4: Vests in three equal installments on February 26, 2019, February 26, 2020 and February 26, 2021.

F5: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.